# Nexgel, Inc.: financial statements, quarterly

NXGL · Nasdaq · CIK 1468929 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nxgl.md) · [Financials](/companies/nxgl/financials.md) · [Filings](/companies/nxgl/filings.md) · [Insiders](/companies/nxgl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nxgl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,221](/filings/0001493152-24-045213.md) | [1,082 d](/filings/0001641172-25-000937.md) | [1,266](/filings/0001641172-25-009988.md) | [1,440](/filings/0001641172-25-023236.md) | [2,940](/filings/0001493152-25-021738.md) | [3,041 d](/filings/0001493152-26-014377.md) | [2,806](/filings/0001493152-26-023207.md) | [2,884](/filings/0001493152-26-038555.md) | [2,934](/filings/0001493152-25-021738.md) | [2,796 d](/filings/0001493152-26-014377.md) | [2,650](/filings/0001493152-26-023207.md) | [3,686](/filings/0001493152-26-038555.md) |
| Cost of revenue | $k | [877](/filings/0001493152-24-045213.md) | [1,169 d](/filings/0001641172-25-000937.md) | [1,106](/filings/0001641172-25-009988.md) | [1,147](/filings/0001641172-25-023236.md) | [1,785](/filings/0001493152-25-021738.md) | [1,967 d](/filings/0001493152-26-014377.md) | [1,618](/filings/0001493152-26-023207.md) | [1,626](/filings/0001493152-26-038555.md) | [1,691](/filings/0001493152-25-021738.md) | [1,977 d](/filings/0001493152-26-014377.md) | [1,589](/filings/0001493152-26-023207.md) | [2,577](/filings/0001493152-26-038555.md) |
| Gross profit | $k | [344](/filings/0001493152-24-045213.md) | [(87.0) d](/filings/0001641172-25-000937.md) | [160](/filings/0001641172-25-009988.md) | [293](/filings/0001641172-25-023236.md) | [1,155](/filings/0001493152-25-021738.md) | [1,074 d](/filings/0001493152-26-014377.md) | [1,188](/filings/0001493152-26-023207.md) | [1,258](/filings/0001493152-26-038555.md) | [1,243](/filings/0001493152-25-021738.md) | [819 d](/filings/0001493152-26-014377.md) | [1,061](/filings/0001493152-26-023207.md) | [1,109](/filings/0001493152-26-038555.md) |
| Research and development | $k | [6.0](/filings/0001493152-24-045213.md) | [13.0 d](/filings/0001641172-25-000937.md) | [2.0](/filings/0001641172-25-009988.md) | [76.0](/filings/0001641172-25-023236.md) | [0.0 d](/filings/0001493152-25-021738.md) | [0.0 d](/filings/0001493152-26-014377.md) | [1.0](/filings/0001493152-26-023207.md) | [0.0 d](/filings/0001493152-26-038555.md) | [7.0](/filings/0001493152-25-021738.md) | [(6.0) d](/filings/0001493152-26-014377.md) | not reported | [20.0](/filings/0001493152-26-038555.md) |
| Selling, general and administrative | $k | [950](/filings/0001493152-24-045213.md) | [1,119 d](/filings/0001641172-25-000937.md) | [1,029](/filings/0001641172-25-009988.md) | [1,271](/filings/0001641172-25-023236.md) | [1,943](/filings/0001493152-25-021738.md) | [1,915 d](/filings/0001493152-26-014377.md) | [1,964](/filings/0001493152-26-023207.md) | [1,894](/filings/0001493152-26-038555.md) | [1,961](/filings/0001493152-25-021738.md) | [2,039 d](/filings/0001493152-26-014377.md) | [2,019](/filings/0001493152-26-023207.md) | [3,594](/filings/0001493152-26-038555.md) |
| Operating income | $k | [(612)](/filings/0001493152-24-045213.md) | [(1,219) d](/filings/0001641172-25-000937.md) | [(871)](/filings/0001641172-25-009988.md) | [(1,054)](/filings/0001641172-25-023236.md) | [(788)](/filings/0001493152-25-021738.md) | [(841) d](/filings/0001493152-26-014377.md) | [(777)](/filings/0001493152-26-023207.md) | [(636)](/filings/0001493152-26-038555.md) | [(725)](/filings/0001493152-25-021738.md) | [(1,214) d](/filings/0001493152-26-014377.md) | [(958)](/filings/0001493152-26-023207.md) | [(2,505)](/filings/0001493152-26-038555.md) |
| Interest expense | $k | [3.0](/filings/0001493152-23-040625.md) | [2.0 d](/filings/0001493152-24-014127.md) | [15.0](/filings/0001493152-24-018950.md) | [30.0](/filings/0001493152-24-032936.md) | [20.0](/filings/0001493152-24-045213.md) | [14.0 d](/filings/0001493152-26-014377.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(550)](/filings/0001493152-24-045213.md) | [(1,098) d](/filings/0001641172-25-000937.md) | [(853)](/filings/0001641172-25-009988.md) | [(885)](/filings/0001641172-25-023236.md) | [(693)](/filings/0001493152-25-021738.md) | [(850) d](/filings/0001493152-26-014377.md) | [(712)](/filings/0001493152-26-023207.md) | [(665)](/filings/0001493152-26-038555.md) | [(653)](/filings/0001493152-25-021738.md) | [(970) d](/filings/0001493152-26-014377.md) | [(927)](/filings/0001493152-26-023207.md) | [(3,635)](/filings/0001493152-26-038555.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001493152-24-045213.md) | not reported | [(0.14)](/filings/0001641172-25-009988.md) | [(0.14)](/filings/0001641172-25-023236.md) | [(0.11)](/filings/0001493152-25-021738.md) | not reported | [(0.09)](/filings/0001493152-26-023207.md) | [(0.09)](/filings/0001493152-26-038555.md) | [(0.08)](/filings/0001493152-25-021738.md) | not reported | [(0.11)](/filings/0001493152-26-023207.md) | [(0.40)](/filings/0001493152-26-038555.md) |
| Basic EPS | $ per share | [(0.10)](/filings/0001493152-24-045213.md) | not reported | [(0.14)](/filings/0001641172-25-009988.md) | [(0.14)](/filings/0001641172-25-023236.md) | [(0.11)](/filings/0001493152-25-021738.md) | not reported | [(0.09)](/filings/0001493152-26-023207.md) | [(0.09)](/filings/0001493152-26-038555.md) | [(0.08)](/filings/0001493152-25-021738.md) | not reported | [(0.11)](/filings/0001493152-26-023207.md) | [(0.40)](/filings/0001493152-26-038555.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.3](/filings/0001493152-23-040625.md) | [2.7](/filings/0001493152-24-045213.md) | [2.4](/filings/0001493152-24-018950.md) | [1.1](/filings/0001493152-24-032936.md) | [1.1](/filings/0001493152-25-021738.md) | [1.8](/filings/0001493152-25-021738.md) | [1.2](/filings/0001493152-26-023207.md) | [0.7](/filings/0001493152-26-038555.md) | [0.9](/filings/0001493152-25-021738.md) | [0.3](/filings/0001493152-26-038555.md) | [0.2](/filings/0001493152-26-023207.md) | [0.5](/filings/0001493152-26-038555.md) |
| Current assets | $m | [5.9](/filings/0001493152-23-040625.md) | [5.1](/filings/0001641172-25-000937.md) | [4.9](/filings/0001493152-24-018950.md) | [3.6](/filings/0001493152-24-032936.md) | [4.6](/filings/0001493152-24-045213.md) | [5.1](/filings/0001493152-26-014377.md) | [4.7](/filings/0001641172-25-009988.md) | [4.2](/filings/0001641172-25-023236.md) | [5.6](/filings/0001493152-25-021738.md) | [4.3](/filings/0001493152-26-038555.md) | [5.6](/filings/0001493152-26-023207.md) | [6.2](/filings/0001493152-26-038555.md) |
| Total assets | $m | [9.9](/filings/0001493152-23-040625.md) | [10.0](/filings/0001641172-25-000937.md) | [10.4](/filings/0001493152-24-018950.md) | [9.8](/filings/0001493152-24-032936.md) | [10.6](/filings/0001493152-24-045213.md) | [11.0](/filings/0001493152-26-014377.md) | [10.4](/filings/0001641172-25-009988.md) | [9.7](/filings/0001641172-25-023236.md) | [11.6](/filings/0001493152-25-021738.md) | [10.5](/filings/0001493152-26-038555.md) | [11.6](/filings/0001493152-26-023207.md) | [26.4](/filings/0001493152-26-038555.md) |
| Current liabilities | $m | [1.6](/filings/0001493152-23-040625.md) | [2.5](/filings/0001641172-25-000937.md) | [2.5](/filings/0001493152-24-018950.md) | [2.6](/filings/0001493152-24-032936.md) | [3.0](/filings/0001493152-24-045213.md) | [2.5](/filings/0001493152-26-014377.md) | [2.5](/filings/0001641172-25-009988.md) | [2.4](/filings/0001641172-25-023236.md) | [3.3](/filings/0001493152-25-021738.md) | [3.0](/filings/0001493152-26-038555.md) | [3.3](/filings/0001493152-26-023207.md) | [14.4](/filings/0001493152-26-038555.md) |
| Total liabilities | $m | [3.7](/filings/0001493152-23-040625.md) | [4.8](/filings/0001641172-25-000937.md) | [5.2](/filings/0001493152-24-018950.md) | [5.2](/filings/0001493152-24-032936.md) | [5.6](/filings/0001493152-24-045213.md) | [4.9](/filings/0001493152-26-014377.md) | [4.9](/filings/0001641172-25-009988.md) | [4.7](/filings/0001641172-25-023236.md) | [6.0](/filings/0001493152-25-021738.md) | [5.6](/filings/0001493152-26-038555.md) | [7.1](/filings/0001493152-26-023207.md) | [21.0](/filings/0001493152-26-038555.md) |
| Long-term debt | $m | [0.3](/filings/0001493152-23-040625.md) | [0.6](/filings/0001493152-24-014127.md) | [0.8](/filings/0001493152-24-018950.md) | [0.7](/filings/0001493152-24-032936.md) | [0.7](/filings/0001493152-24-045213.md) | [0.7](/filings/0001641172-25-000937.md) | [0.7](/filings/0001641172-25-009988.md) | [0.6](/filings/0001641172-25-023236.md) | [0.6](/filings/0001493152-25-021738.md) | [0.6](/filings/0001493152-26-014377.md) | [0.6](/filings/0001493152-26-023207.md) | not reported |
| Short-term borrowings | $m | [0.1](/filings/0001493152-23-040625.md) | [0.2](/filings/0001641172-25-000937.md) | not reported | not reported | [0.3](/filings/0001493152-24-045213.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [5.7](/filings/0001493152-23-040625.md) | [4.7](/filings/0001641172-25-000937.md) | [4.8](/filings/0001493152-24-018950.md) | [4.2](/filings/0001493152-24-032936.md) | [4.7](/filings/0001493152-24-045213.md) | [5.8](/filings/0001493152-26-014377.md) | [5.2](/filings/0001641172-25-009988.md) | [4.7](/filings/0001641172-25-023236.md) | [5.2](/filings/0001493152-25-021738.md) | [4.5](/filings/0001493152-26-038555.md) | [4.0](/filings/0001493152-26-023207.md) | [4.9](/filings/0001493152-26-038555.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(723) d](/filings/0001493152-24-045213.md) | [(587) d](/filings/0001641172-25-000937.md) | [(1,092)](/filings/0001641172-25-009988.md) | [(700) d](/filings/0001641172-25-023236.md) | [(1,216) d](/filings/0001493152-25-021738.md) | [(859) d](/filings/0001493152-26-014377.md) | [(400)](/filings/0001493152-26-023207.md) | [(407) d](/filings/0001493152-26-038555.md) | [(785) d](/filings/0001493152-25-021738.md) | [281 d](/filings/0001493152-26-014377.md) | [(504)](/filings/0001493152-26-023207.md) | [(2,197) d](/filings/0001493152-26-038555.md) |
| Capital expenditure | $k | [358 d](/filings/0001493152-24-045213.md) | [85.0 d](/filings/0001641172-25-000937.md) | [152](/filings/0001641172-25-009988.md) | [209 d](/filings/0001641172-25-023236.md) | [13.0 d](/filings/0001493152-25-021738.md) | [69.0 d](/filings/0001493152-26-014377.md) | not reported | not reported | [8.0 d](/filings/0001493152-25-021738.md) | [40.0 d](/filings/0001493152-26-014377.md) | [9.0](/filings/0001493152-26-023207.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,572](/filings/0001493152-23-040625.md) | [5,586](/filings/0001493152-24-018950.md) | [5,662](/filings/0001493152-24-032936.md) | [5,714](/filings/0001493152-24-045213.md) | [5,982](/filings/0001641172-25-009988.md) | [6,255](/filings/0001641172-25-023236.md) | [6,569](/filings/0001493152-25-021738.md) | [7,645](/filings/0001493152-26-023207.md) | [7,654](/filings/0001493152-26-038555.md) | [7,971](/filings/0001493152-25-021738.md) | [8,204](/filings/0001493152-26-023207.md) | [9,013](/filings/0001493152-26-038555.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,747,663 at 2026-08-14, from the cover of the [10-Q filed 2026-08-17](/filings/0001493152-26-038555.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.